Pharma Giants Vie for Market Dominance with Lipoprotein(a) Treatments

A race is heating up among pharmaceutical giants Novartis, Amgen, and Eli Lilly as they advance novel drugs designed to reduce Lipoprotein(a) levels by up to 100 percent.

The treatments target a multi-billion-dollar cardiology market, but experts warn that the high cost of these biological therapies may lead to an equity crisis in developing nations across Africa.

Lipoprotein(a), or Lp(a), is a genetic cardiovascular risk factor that cannot be reduced through diet, exercise, or traditional statin therapy.

The pharmaceutical sector has developed targeted RNA-interference and antisense oligonucleotide therapies designed to inhibit the synthesis of the protein in the liver, with early Phase 2 data showing dramatic biochemical reductions.